Brokerages predict that ITUS Corporation (NYSE:ANIX) will announce earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Zero analysts have made estimates for ITUS’s earnings. ITUS reported earnings per share of ($0.08) in the same quarter last year, which suggests a negative year-over-year growth rate of 187.5%. The firm is expected to announce its next earnings report on Monday, June 10th.
According to Zacks, analysts expect that ITUS will report full year earnings of ($0.93) per share for the current fiscal year. For the next year, analysts anticipate that the business will post earnings of ($0.94) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover ITUS.
ITUS (NYSE:ANIX) last issued its earnings results on Wednesday, March 13th. The company reported ($0.23) EPS for the quarter.
In other ITUS news, Director Lewis H. Titterton, Jr. bought 50,000 shares of the firm’s stock in a transaction dated Monday, April 22nd. The stock was acquired at an average price of $4.09 per share, for a total transaction of $204,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Amit Kumar bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were acquired at an average price of $4.27 per share, with a total value of $42,700.00. The disclosure for this purchase can be found here. Insiders acquired 74,900 shares of company stock valued at $310,638 in the last 90 days.
NYSE ANIX traded down $0.11 during trading hours on Friday, hitting $4.17. The company had a trading volume of 9,200 shares, compared to its average volume of 60,943. ITUS has a 1-year low of $2.96 and a 1-year high of $6.86.
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Featured Story: What is a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.